Long noncoding RNAs (lncRNAs) play an important role in the proliferation and metastasis of osteosarcoma. Identification of the pathogenesis of osteosarcoma and development of new therapeutic strategies against osteosarcoma are urgently needed. In this study, we evaluated the expression of TUG1 (Taurine Upregulated Gene 1) in osteosarcoma tissues and selected it as our target for further analyses. In vitro, we found that TUG1 was upregulated by FOXM1 (Forkhead Box M1) in osteosarcoma cells. TUG1 accelerated osteosarcoma proliferation, migration, and invasion by competitively sponging miR-219a-5p, leading to upregulation of Phosphatidylinositol-4, 5-Bisphosphate 3-Kinase Catalytic Subunit Alpha and activation of the protein kinase B (AKT) signaling pathway. In addition, the AKT pathway activation promoted TUG1 expression by upregulating the expression of FOXM1, forming a positive feedback loop in osteosarcoma. Furthermore, we designed and synthesized therapeutic locked nucleic acids targeting TUG1. The proliferation of osteosarcoma was significantly repressed. Hence, TUG1 may be a potential biomarker and therapeutic target for osteosarcoma.
Since then, no significant progress has been made in improving osteosarcoma diagnosis and treatment. 4 In studies exploring treatments for osteosarcoma, signaling pathways related to tumor formation, proliferation and metastasis have received increased attention, [5] [6] [7] [8] but the outlook remains unclear. Therefore, it is imperative to clarify the intrinsic mechanism of osteosarcoma and identify potential diagnostic and prognostic biomarkers of osteosarcoma.
An extensive array of functional mutations with profound effects on the expression of long noncoding RNAs (lncRNAs) was identified by genome mutation analysis of cancer within the noncoding genome. 9, 10 As a multifarious class of transcripts, lncRNAs have a length >200 nucleotides and a limited protein-coding ability 11, 12 and display a unique expression pattern in different tissues, organs or specific tumor types. 13 lncRNAs participate in multiple cell phenomena, such as regulation of gene expression, including recruiting transcription-modifying complexes to influence specific gene expression [14] [15] [16] and interacting with microRNAs (miRNAs), mRNAs or proteins for post-transcriptional regulation. [17] [18] [19] Increasing research has shown that lncRNAs serve as signals of cell behavior, identify the intrinsic pathogenesis of cancer, and have prognostic or therapeutic value. 20 However, the basic function of lncRNAs in osteosarcoma is still unclear. In this study, we explored the roles of lncRNAs in osteosarcoma and investigated the diagnostic and treatment implications for osteosarcoma.
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Taurine upregulated gene 1 (TUG1), a 7542 bp highly conserved lncRNA, was originally identified in taurine-induced retinal cells 21 and are expressed in many human tumors, such as glioblastoma, prostate cancer, and hepatocellular carcinoma. [22] [23] [24] TUG1 is distributed in the cytoplasm and nucleus, and its function begins with its cellular localization. In the nucleus, TUG1 can interact with Polycomb Repressive Complex 2 (PRC2) and suppress cell-cycle-related gene expression. 25 However, TUG1's cytoplasmic function and its influence on osteosarcoma are not clear. In this study, we found that University. The HCT116 dicer ex5 cell line has a mutant DICER with an insertion disruption in the N-terminal helicase domain (exon 5). This hypomorphic mutation in DICER impairs its function in the maturation of the vast majority of miRNAs. 23 All cell lines were grown in penicillin/streptomycin at 37°C in a humidified atmosphere with 5% CO 2 .
| MATERIALS AND METHODS

| Patients and tissue samples
| RNA extraction and quantitative real-time PCR
The cytoplasmic and nuclear fractions were separated using the PARIS protocol (Life Technologies, Carlsbad, CA, USA Table S1 .
| Plasmid construction, cell transfection, and
RNA interference
The cDNAs encoding FOXM1 and PIK3CA were PCR-amplified by a Table S1 . Transfection of siRNAs, miRNA mimics or inhibitors was performed using Lipofectamine RNAiMAX (Invitrogen) at a final concentration of 100 nmol/L. 
| Dual-luciferase reporter assay
| Wound healing assay
After transfection for 24 hours, cells were seeded into 6-well plates (Corning). An artificial wound was made using a 200 μL pipette tip across the cell monolayer. For measurement of wound healing, images were taken at 0, 24, and 48 hours, and the percentage of wound healing was calculated using ImageJ software. Each experiment was carried out in triplicate independent experiments.
| Transwell migration assay
The cells were resuspended in serum-free culture medium at a density of 2. 
| Western blot assay
For the western blot assay, cells were harvested and lysed in radioimmunoprecipitation Assay (RIPA, Beyotime) with protease and phosphatase inhibitors. Each sample was separated in 12% SDS-PAGE and then transferred to PVDF membranes (Sigma, St Louis, MO, USA). The membranes were blocked in Tris-buffered saline with 0.05% Tween-20 milk for 2 hours and immunoblotted with specific primary and secondary antibodies. Sample blots were visualized with a chemiluminescence detection reagent (Amersham, Piscataway, NJ, USA) and analyzed using ImageJ software; The primary antibodies used in this study are listed in Table S2 . 
|
| Statistical analysis
SPSS 18.0 software (SPSS inc., Chicago, IL, USA) was used for all statistical analyses in our study. Data are presented as the mean ± SD and the experiments were repeated at least three times or more.
Student's t test (two-tailed) or one-way ANOVA was used for statistical comparisons between experimental groups. A P < .05 was considered statistically significant.
| RESULTS
| TUG1 is highly expressed in osteosarcoma tissues and cell lines
We extracted RNAs from 19 osteosarcoma samples with adjacent tissues from patients with no therapy history and analyzed them by quantitative real-time PCR. As shown in Figure 1A , TUG1 levels were higher in osteosarcoma tissues than adjacent paratumor tissues. Consistent with the upregulation of TUG1 in osteosarcoma tissues, TUG1 levels were substantially higher in osteosarcoma cell lines than osteoblast cell lines ( Figure 1B ). According to the standards set by the National Comprehensive Cancer Network (NCCN) guidelines, high levels of TUG1 were observed in high-grade and metastatic patients ( Figure 1C,D) . Moreover, according to the overall LI ET AL.
| 3095 survival data obtained from the GEPIA database (http://gepia.cancerpku.cn/), high TUG1 levels in sarcoma patients were correlated with reduced survival percentages ( Figure S1 ).
| TUG1 is upregulated by the AKT/FOXM1 axis in osteosarcoma
We examined the intrinsic mechanism for high TUG1 expression in the osteosarcoma cell line. DNA methyltransferase inhibition had little effect on TUG1 expression in osteosarcoma cells (Figure 2A) . and TUG1, we performed dual luciferase reporter assays using cotransfection of pGL3-TUG1, pRL-TK and an increasing number of pcDNA3.1-FOXM1 plasmids in U2OS cells. As shown in Figure 2E , FOXM1 over-expression increased the activity of the TUG1 promoter in a dose-dependent manner. To confirm which putative site influenced the transactivation ability of FOXM1, we individually mutated the two putative sites and one random site of the TUG1 promoter in pGL3-TUG1 ( Figure 2F ). The mutation of P2 significantly decreased the transactivation of the TUG1 promoter by FOXM1. AKT was reported to promote FOXM1 activation by inducing the phosphorylation of FOXO3 for protein degradation. 27, 28 Knockdown of AKT in osteosarcoma cells restrained the expression of TUG1 ( Figure 2G ). According to previous reports, FOXM1 is highly expressed in osteosarcoma, 29, 30 and these data showed that the enhancement of FOXM1 by AKT in osteosarcoma cells, at least, activates TUG1 transcription by direct binding to the TUG1 promoter.
| TUG1 is necessary for the proliferation and metastasis of osteosarcoma cells
To evaluate the function of TUG1, we designed three different lentiviral shRNA sequences (shRNA #1, #2, #3) to stably knock down TUG1 in osteosarcoma cells, and chose the sh-TUG1 #2 for further experiments ( Figure 3A) . Because of the large size of TUG1
(7542 bp), we could not overexpress it. The CCK8 assay showed that the proliferation of osteosarcoma cells was impaired when TUG1 was knocked down ( Figure 3B ). Colony formation assays similarly concluded that the number of colonies was decreased in TUG1 knockdown cells ( Figure 3C ). Then, we evaluated the influence of Relative expression of TUG1 was examined in metastatic (n = 11) and nonmetastatic (n = 8) osteosarcoma patients. For A, B, C and D, error bars indicate ± SD. *P < .05, **P < .001, ***P < .0001 TUG1 knockdown on osteosarcoma cells by wound healing and transwell assays. As shown in Figure 3D and E, knocking down TUG1
significantly repressed the migration of osteosarcoma cells. The number of invading cells was also decreased in TUG1 knockdown cells ( Figure 3E ). These results indicated that TUG1 was indispensable for the proliferation and metastasis of osteosarcoma cells.
| PIK3CA contributes to TUG1-mediated osteosarcoma cell tumorigenesis and metastasis
Increasing evidence has shown that activation of the PI3K/AKT pathway, MAPK/ERK pathway, and JAK/STAT (signal transducers and activators of transcription) pathway has key roles in osteosarcoma tumorigenesis and metastasis. [31] [32] [33] To elucidate the possible mediators through which TUG1 drives osteosarcoma cell tumorigenesis and metastasis, we performed a western blot assay to analyze the core proteins of each pathway in TUG1 knockdown osteosarcoma cells. As shown in Figure 4A , TUG1 knockdown only decreased AKT at the phosphorylation level but not at the total protein level, consistent with reports that AKT was overexpressed in osteosarcoma cells and tissues. 31 We analyzed the proteins that influence AKT phosphorylation levels in osteosarcoma cells, and only PIK3CA protein levels, as well as mRNA levels, were dramatically decreased in TUG1 knockdown osteosarcoma cells ( Figure 4B, C) . We further investigated whether PIK3CA contributed to TUG1-mediated osteosarcoma cell tumorigenesis and metastasis. Overexpression of PIK3CA | 3099
| TUG1 functions as a sponge for miR-219a-5p to upregulate PIK3CA levels in osteosarcoma cells
The function of lncRNAs is closely related to their subcellular location. 34 It has been reported that TUG1 is distributed within the nucleus and cytoplasm, but the ratio was higher in the cytoplasm. 34 We applied nuclear and cytoplasmic experiments followed by quantitative real-time PCR to test the subcellular localization of TUG1 in osteosarcoma cells. Certainly, TUG1 was mostly localized within the cytoplasm in U2OS and HOS cell lines ( Figure 5A ). As for the location of TUG1, it might function as a competitive endogenous RNA to sponge miRNA, quenching miRNA ability and liberating the miRNA target. To test this premise, we transfected HCT116 and HCT116 dicer ex5 cells with shTUG1. HCT116 cell line of colon cancer has a wild-type DICER, and HCT116 dicer ex5 has a mutant DICER that impairs its function in the maturation of miRNAs. As shown in Figure 5B and C, downregulation of PIK3CA mediated by TUG1 knockdown was abrogated in HCT116 dicer-ex5. These results suggest that TUG1-mediated PIK3CA downregulation is mostly dependent on miRNA activity.
A bioinformatics analysis of Starbase (http://starbase.sysu.edu.cn/) and miRanda (http://www.microrna.org/microrna/home.do) revealed 9 putative miRNAs shared by TUG1 and PIK3CA. We evaluated these miRNA levels in TUG1 knockdown osteosarcoma cells using quantitative real-time PCR. Among the upregulated miRNAs, miR219a-5p was the most significantly upregulated following inhibition of TUG1 ( Figure 5D ). We mutated the binding sites on TUG1 and the 3′-UTR of PIK3CA ( Figure 5E ) and constructed dual luciferase reporters. Co-transfection of miR-219a-5p mimics downregulated the luciferase activity of psiCHECK2-TUG1/PIK3CA. Conversely, psi-CHECK2-TUG1mt/PIK3CAmt reporter activity was not obviously decreased ( Figure 5F ). These results demonstrated that TUG1 and the 3′-UTR of PIK3CA contained binding sites for miR-219a-5p.
Then we explored whether TUG1-mediated downregulation of miR-219a-5p was the reason for the upregulation of PIK3CA. The luciferase activity of PIK3CA was decreased with TUG1 knockdown and was rescued by miR-219a-5p inhibitors, but the luciferase activity of the mutant reporter was not obviously changed ( Figure 5G ).
These data were not only confirmed by the RNA and protein levels of PIK3CA ( Figure 5H , I) but were also confirmed by CCK8, colony formation and transwell assays ( Figure 5J -L). All these data showed that TUG1 functions as a sponge for miR-219a-5p to upregulate PIK3CA levels in osteosarcoma cells.
| Targeting TUG1 promotes tumorigenesis of osteosarcoma in vivo
To assess the potential of TUG1 in the treatment of osteosarcoma in vivo, we synthesized and selected an optimized LNA targeting TUG1 for intravenous injection. We generated a subcutaneous xenograft model of HOS cells in nu/nu mice and injected LNA-TUG1 for 6 weeks. As shown in Figure 6A and B, there were significant changes in the size and weight of tumors between the LNA treatment group and the normal group. Knockdown of TUG1 by LNA was verified by quantitative real-time PCR assays, along with inhibition of PIK3CA at the mRNA and protein levels ( Figure 6C, D) .
In addition, we established a model of TUG1-knockdown HOS cells in nu/nu mice and reached a similar conclusion (Figure 6A-D) . Collectively, the data showed that TUG1 could promote tumorigenesis of osteosarcoma in vivo and that LNA targeting TUG1 had a therapeutic potential for osteosarcoma.
| DISCUSSION
The disease-free survival (DFS) rate is obviously poorer in patients with metastatic disease than those with nonmetastatic disease. 35 In this study, we observed high levels of TUG1 in osteosarcoma tissues and cell lines. TUG1 accelerated osteosarcoma proliferation, TUG1 was shown to be overexpressed in osteosarcoma tissues and cell lines. 36 We verified this conclusion according to the stage of the osteosarcoma and the presence or absence of metastasis and reached a similar conclusion. Through the in vitro study, we evaluated the influence of TUG1-knockdown on osteosarcoma cells and confirmed the conclusion of clinical sample statistics. According to previous reports, TUG1 expression is induced by p53 in non-small cell lung cancer cells, 36 Sp1 in hepatocellular carcinoma, 24 and RBPJ (recombination signal binding protein for immunoglobulin kappa J region) and MYC in glioma. 22 We overexpressed these transcription factors in osteosarcoma cell lines, and none of these could significantly promote the expression of TUG1. Through bioinformatics prediction of the TUG1 promoter region, we confirmed that FOXM1
induced high expression of TUG1 in osteosarcoma cell lines. FOXM1
is overexpressed in many different tumors, including osteosarcoma, and contributes to cell proliferation and metastasis. 37, 38 It has been reported that the PI3K/AKT pathway can stimulate the phosphorylation of FOXO3 at Ser294, Ser253, and Thr32 and then eliminate the negative regulation of FOXM1. 28 We assumed that FOX proteins may influence the expression of TUG1 and showed that FOXM1 could bind to the promoter region of TUG1 by luciferase reporter assays. These data indicated that the expression and activity of TUG1 are controlled by different transcription factors in various tissues. We evaluated changes in proliferation and metastasis-related signaling pathways in TUG1 knockdown osteosarcoma cell lines and found that only the PI3K/AKT pathway was obviously suppressed.
We found that PIK3CA was downregulated not only at the mRNA level but also at the protein level. The PI3K/AKT signaling pathway can influence the proliferation and metastasis of tumors. This pathway was found to be overactivated in many cancers. 39, 40 PI3K receives many cell signals from numerous receptor tyrosine kinases (RTKs) and interactions with the AKT pathway. PIK3CA, a component of PI3K, has been found to be overexpressed in osteosarcoma tissues 31, 41 and described as an oncogene. In our study, the overexpression of PIK3CA in TUG1-knockdown osteosarcoma cells and Nuclear Enriched Abundant Transcript 1 (NEAT1), participate in the formation of the nucleus and regulate gene transcription. 42, 43 In this study, we showed that high levels of TUG1 were distributed in the cytoplasm, indicating that it might act as a ceRNA to regulate PIK3CA in osteosarcoma. A recent study showed that by competing with SOX2 in glioma and phosphatase and tensin homolog (PTEN) in prostate cancer, TUG1 acts as either a tumor suppressor or oncogenic factor. As shown by our data, we assessed this hypothesis and found that miR-219a-5p was the link between TUG1 and PIK3CA. There may be a regulatory network of osteosarcoma-related genes, which is mediated by TUG1 sponging miRNAs. Through this network, TUG1 can widely influence the expression of pivotal components of osteosarcoma driver genes and serve as an oncogene or a tumor suppressor.
Understanding the basic mechanism of osteosarcoma could be beneficial for the improvement and development of therapies for osteosarcoma patients. Our in vivo data showed that inhibition of TUG1 by therapeutic LNAs repressed the proliferation of osteosarcoma cells, indicating that TUG1 targeting may be useful as a therapeutic method for osteosarcoma patients. In summary, our studies
showed that TUG1 could function as a clinical biomarker for the diagnosis of osteosarcoma but also as a promising target for therapy.
